GlassScriptPhysician profile
Mubashar H Khan
NPI 1497175707
$24,650.80
in general payments reported to CMS, 2019-2025
41 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $281 · 2021: $935 · 2022: $1,072 · 2023: $2,788 · 2024: $899 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Travel and Lodging: $966 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.04 |
| Travel and Lodging | $966.13 |
| Education | $120.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13,497.28 | 2019-2023 | Lifevest |
| Medtronic Vascular, INC. | $2,602.39 | 2019 | |
| Boston Scientific Corporation | $1,688.46 | 2019-2023 | Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $939.62 | 2020-2025 | |
| Amgen INC. | $588.77 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $549.36 | 2021-2025 | Symplicity G3, Linq II |
| Janssen Pharmaceuticals, INC | $490.50 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $442.49 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $428.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $426.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $339.67 | 2019-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $309.97 | 2019 | |
| Jenavalve Technology, INC. | $256.50 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $207.21 | 2019-2025 | Evkeeza |
| Amarin Pharma, INC. | $198.20 | 2021-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $170.99 | 2021-2025 | Watchpatone |
| Abbott Laboratories | $141.63 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $139.69 | 2024-2025 | Tryvio |
| Astrazeneca Pharmaceuticals LP | $133.81 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $128.77 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.04 | 2021-2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $80.46 | 2023 | Arcalyst |
| Philips North America LLC | $77.31 | 2023-2025 | Extended Holter |
| Recor Medical INC | $68.05 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Inspire Medical Systems, INC. | $63.33 | 2023 | Inspire |
| Impulse Dynamics (USA) INC. | $61.62 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $60.33 | 2021-2025 | |
| Azurity Pharmaceuticals, INC. | $55.69 | 2023 | Edarbi |
| Heartflow, INC. | $48.52 | 2021-2023 | Ffrct |
| Sanofi-Aventis U.S. LLC | $44.92 | 2019-2024 | |
| Abiomed | $43.64 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $41.43 | 2023-2024 | Inpefa |
| Vifor Pharma, INC. | $38.97 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $37.72 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $32.48 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $26.47 | 2019 | |
| Baxter Healthcare | $19.65 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Bridgebio Pharma, INC. | $18.25 | 2025 | Attruby |
| Althera Pharmaceuticals LLC | $15.97 | 2022 | |
| Livanova USA, INC. | $13.14 | 2019 | |
| Lundbeck LLC | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mubashar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.